Coherus BioSciences, Inc. (CHRS) Key Metrics
CHRS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $153.0M
- Enterprise value
- $128.2M
- P/E (TTM)
- — 10-yr median 11.0
- Forward P/E
- 41.2
- PEG ratio
- —
- Price / sales
- 3.0 10-yr median 3.7
- Price / book
- 3.2 10-yr median 12.4
- EV / EBITDA
- 3.5 10-yr median 8.3
- Dividend yield
- —
- Beta
- 0.99
CHRS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCHRS valuation Price multiples at each fiscal year-end price.
Price / sales+582.8%
4.1
2025 · hover or tap a bar for each year
20162025
Price / book
2.8
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−68.1 pts
−81.0%
2025 · hover or tap a bar for each year
20162025
CHRS returns How much profit the business earns on the capital it uses.
Return on assets−53.5 pts
−48.2%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−320.8 pts
−328.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover−75.9%
0.12
2025 · hover or tap a bar for each year
20162025
CHRS per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−84.9%
$0.35
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$1.41
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.15
2025 · hover or tap a bar for each year
20162025
Book value per share
$0.51
2025 · hover or tap a bar for each year
20162025
Shares outstanding+4.8%
120.4M
2025 · hover or tap a bar for each year
20162025
CHRS financial health Debt, liquidity and how easily interest is covered.
Debt / equity
0.66
2025 · hover or tap a bar for each year
20162025
Net debt−$275.7M
−$131.8M
2025 · hover or tap a bar for each year
20162025
Current ratio+20.7%
1.46
2025 · hover or tap a bar for each year
20162025
Interest coverage
-19.9
2025 · hover or tap a bar for each year
20162025
Debt / assets−74.1%
0.16
2025 · hover or tap a bar for each year
20162025
CHRS efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+347 days
609 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+548 days
754 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+296 days
395 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+599 days
968 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
CHRS valuation history
Fiscal year-endToday10-year median
CHRS returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CHRS debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CHRS cash returned to shareholders
DividendsBuybacksFree cash flow
CHRS price vs earnings per share
Share price at year-endEPS (right axis)
CHRS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $170.9M | $158.5M | $313.6M | $614.8M | $1.20B | $1.45B | $1.32B | $588.6M | $467.6M | $1.18B |
| Enterprise value | $39.1M | $302.4M | $676.7M | $903.6M | $1.21B | $1.33B | $1.32B | $619.3M | $442.5M | $1.16B |
| P/E ratio | — | 5.6 | — | — | — | 11.0 | 14.7 | — | — | — |
| Price / sales | 4.1 | 0.6 | 1.2 | 2.9 | 3.7 | 3.0 | 3.7 | 378.3 | 300.5 | 6.2 |
| Price / book | 2.8 | — | — | — | 12.3 | 5.2 | 12.5 | — | 15.3 | 61.0 |
| Price / free cash flow | — | — | — | — | — | 9.9 | 85.2 | — | — | — |
| Price / operating cash flow | — | — | — | — | — | 9.4 | 46.5 | — | — | — |
| EV / sales | 0.9 | 1.1 | 2.6 | 4.3 | 3.7 | 2.8 | 3.7 | 398.0 | 284.4 | 6.1 |
| EV / EBITDA | — | 5.0 | — | — | — | 8.3 | 11.9 | — | — | — |
| EV / free cash flow | — | — | — | — | — | 9.0 | 85.4 | — | — | — |
| Earnings yield | −99.6% | 18.0% | −75.9% | −47.5% | −23.8% | 9.1% | 6.8% | −35.6% | −50.9% | −10.8% |
| Free cash flow yield | −81.0% | −12.9% | −55.9% | −39.5% | −3.2% | 10.1% | 1.2% | −27.2% | −43.8% | −22.0% |
| Dividend yield | — | — | — | 0.6% | 0.1% | 1.4% | 5.5% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | 1.1% | 1.2% | 0.3% | 1.5% | 5.5% | 0.0% | 0.1% | 0.0% |
| Share price at fiscal year-end | $1.42 | $1.38 | $3.33 | $7.92 | $15.96 | $17.38 | $18.00 | $9.05 | $8.80 | $28.15 |
| Per share | ||||||||||
| Revenue per share | $0.35 | $2.32 | $2.73 | $2.72 | $4.33 | $5.70 | $4.87 | $0.02 | $0.03 | $4.54 |
| Earnings per share | −$1.41 | $0.25 | −$2.53 | −$3.76 | −$3.81 | $1.58 | $1.23 | −$3.22 | −$4.48 | −$3.04 |
| Operating cash flow per share | −$1.15 | −$0.18 | −$1.86 | −$3.11 | −$0.50 | $1.85 | $0.39 | −$2.45 | −$3.77 | −$6.03 |
| Free cash flow per share | −$1.15 | −$0.18 | −$1.86 | −$3.13 | −$0.51 | $1.76 | $0.21 | −$2.46 | −$3.86 | −$6.18 |
| Cash per share | $1.43 | $1.10 | $1.25 | $2.47 | $5.53 | $6.48 | $2.43 | $1.11 | $2.39 | $2.98 |
| Book value per share | $0.51 | −$1.15 | −$2.05 | −$1.77 | $1.30 | $3.37 | $1.44 | −$0.59 | $0.57 | $0.46 |
| Tangible book value per share | $0.12 | −$1.62 | −$2.82 | −$1.85 | $1.25 | $3.32 | $1.39 | −$0.65 | $0.51 | $0.38 |
| Dividends per share | — | — | — | $0.05 | $0.02 | $0.24 | $0.99 | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.03 | $0.02 | $0.09 | $0.18 | $0.01 | $0.09 | $0.16 |
| Debt per share | $0.34 | $2.35 | $5.11 | $6.19 | $5.55 | $5.00 | $2.47 | $1.59 | $1.92 | $2.41 |
| Shares outstanding | 120.4M | 114.8M | 94.2M | 77.6M | 75.4M | 83.5M | 73.2M | 65.0M | 53.1M | 41.9M |
| Change in shares outstanding | +4.8% | +21.9% | +21.3% | +2.9% | −9.6% | +14.1% | +12.5% | +22.4% | +26.8% | +12.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −151.6% | 68.5% | 269.7% | — | −954.8% | — |
| Return on invested capital (ROIC) | — | −61.5% | −100.0% | −161.8% | −162.5% | 114.9% | 208.1% | — | — | — |
| Return on assets (ROA) | −48.2% | 5.3% | −42.8% | −50.3% | −37.8% | 21.1% | 35.3% | −159.8% | −139.6% | −65.2% |
| Return on tangible assets | −80.3% | 7.2% | −42.6% | −61.4% | −42.5% | 15.8% | 22.2% | −218.3% | −149.7% | −72.8% |
| Free cash flow margin | −328.4% | −7.7% | −68.1% | −115.2% | −11.9% | 30.9% | 4.3% | — | — | −136.3% |
| Income quality (OCF / net income) | — | −0.72 | — | — | — | 1.17 | 0.32 | — | — | — |
| Financial health | ||||||||||
| Total debt | $40.3M | $269.9M | $480.8M | $480.4M | $419.0M | $417.1M | $180.6M | $103.1M | $101.8M | $101.1M |
| Cash & short-term investments | $172.1M | $126.0M | $117.7M | $191.7M | $417.2M | $541.2M | $177.7M | $72.4M | $126.9M | $124.9M |
| Net debt | −$131.8M | $143.9M | $363.1M | $288.7M | $1.8M | −$124.1M | $2.9M | $30.7M | −$25.1M | −$23.8M |
| Debt / equity | 0.66 | — | — | — | 4.29 | 1.48 | 1.72 | — | 3.34 | 5.23 |
| Debt / assets | 0.16 | 0.60 | 0.76 | 1.00 | 0.62 | 0.50 | 0.44 | 1.04 | 0.63 | 0.57 |
| Net debt / EBITDA | — | 2.36 | — | — | — | −0.78 | 0.03 | — | — | — |
| Current ratio | 1.46 | 1.21 | 1.43 | 2.75 | 3.64 | 5.27 | 3.26 | 2.18 | 4.47 | 2.22 |
| Quick ratio | 1.43 | 0.96 | 1.24 | 2.47 | 3.42 | 4.97 | 2.78 | 2.13 | 4.47 | 2.30 |
| Interest coverage | -19.9 | -4.1 | -5.0 | -7.9 | -11.5 | 7.4 | 6.1 | -21.1 | -24.3 | -14.5 |
| Working capital | $64.8M | $58.6M | $143.9M | $242.5M | $437.0M | $621.8M | $259.8M | $39.1M | $98.5M | $68.6M |
| Invested capital | −$70.8M | $11.9M | $169.7M | $151.3M | $99.6M | $156.9M | $108.1M | −$7.9M | $5.5M | −$4.5M |
| Tangible asset value | $14.8M | −$185.6M | −$265.1M | −$143.3M | $94.2M | $277.4M | $101.7M | −$42.2M | $27.0M | $15.8M |
| Net current asset value | $9.4M | −$238.9M | −$347.4M | −$237.0M | $20.7M | $206.8M | $71.0M | −$65.7M | −$5.2M | −$34.2M |
| Graham number | — | — | — | — | — | $10.95 | $6.30 | — | — | — |
| Graham net-net per share | −$0.08 | −$2.85 | −$5.08 | −$4.18 | −$0.71 | $1.44 | $0.11 | −$1.02 | −$0.10 | −$0.84 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $3.7M | $1.8M | $20.3M | $72.1M | — | $0 | $0 |
| Share buybacks (net) | — | — | $3.6M | $3.7M | $1.8M | $880,000 | $815,000 | $0 | $544,000 | $0 |
| Dividend payout ratio | — | — | — | — | — | 15.4% | 80.3% | — | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 14.4% | 472.0% | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.1% | 1.0% | 0.4% | 1.5% | 3.6% | 50.7% | 293.9% | 3.4% |
| Capex / operating cash flow | — | — | — | — | — | 4.7% | 45.5% | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.08 | 0.55 | 0.37 | 2.50 | 3.96 | 0.24 | 1.35 | 2.17 |
| Stock-based compensation / revenue | 40.2% | 10.4% | 16.8% | 24.0% | 15.7% | 8.0% | 9.4% | 2,236.3% | 2,317.8% | 14.4% |
| R&D / revenue | 248.9% | 35.0% | 42.5% | 94.5% | 111.2% | 30.0% | 26.5% | 7,084.8% | 10,436.3% | 133.8% |
| SG&A / revenue | 238.6% | 56.4% | 72.2% | 94.0% | 52.0% | 29.2% | 38.5% | 6,232.5% | 4,582.5% | 27.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 609.1 | 261.7 | 262.8 | 201.5 | 156.5 | 114.7 | 71.9 | -408.6 | — | 3.3 |
| Days of inventory on hand | 753.8 | 206.0 | 116.4 | 199.0 | 259.5 | 481.1 | 606.2 | 93.6 | — | -6.6 |
| Days payables outstanding | 394.8 | 98.9 | 53.7 | 72.1 | 99.4 | 199.5 | 441.1 | 1,749.3 | 41.3 | 35.9 |
| Cash conversion cycle (days) | 968.1 | 368.9 | 325.6 | 328.4 | 316.6 | 396.3 | 237.0 | -2,064.3 | — | -39.2 |
| Receivables turnover | 0.60 | 1.39 | 1.39 | 1.81 | 2.33 | 3.18 | 5.08 | — | — | 111.21 |
| Payables turnover | 0.92 | 3.69 | 6.80 | 5.06 | 3.67 | 1.83 | 0.83 | 0.21 | 8.85 | 10.16 |
| Inventory turnover | 0.48 | 1.77 | 3.14 | 1.83 | 1.41 | 0.76 | 0.60 | 3.90 | — | — |
| Asset turnover | 0.12 | 0.50 | 0.46 | 0.36 | 0.43 | 0.76 | 1.40 | 0.01 | 0.01 | 0.97 |
| Average receivables | $70.4M | $191.4M | $185.2M | $116.5M | $140.0M | $149.5M | $70.1M | −$1.7M | — | $1.7M |
| Average payables | $19.2M | $31.8M | $23.4M | $13.8M | $15.7M | $20.6M | $20.6M | $15.5M | $18.1M | $25.0M |
| Average inventory | $36.6M | $66.3M | $50.7M | $38.2M | $40.9M | $49.7M | $28.4M | $829,500 | −$2.4M | −$4.6M |
| Intangibles / total assets | 17.9% | 12.0% | 11.4% | 1.2% | 0.5% | 0.4% | 0.9% | 3.6% | 2.2% | 2.0% |
Computed from CHRS's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CHRS valuation and financial ratios
It ended the year with $40.3 million of debt and $172.1 million in cash and short-term investments, a net cash position of $131.8 million. The share count rose 187.2% from 41.9M to 120.4M over 9 years.
See the CHRS income statement, the CHRS chart for price history, or the CHRS stock overview for the latest quote and news.
CHRS key metrics FAQ
How much debt does Coherus BioSciences have?
Coherus BioSciences had total debt of $40.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.66 and more cash than debt.
What is Coherus BioSciences's free cash flow yield?
Coherus BioSciences generated -$138.5 million of free cash flow in fiscal 2025, a free cash flow yield of −81.0% on its market value at year-end ($170.9 million).
What is Coherus BioSciences's current ratio?
Coherus BioSciences's current ratio was 1.46 at the end of fiscal 2025: current assets were 1.46 times current liabilities.